 The aim of this study is to analyse the efficacy and the safety of the combination of pentoxyphilline 400 mg, twice a day and tocopherol 500 mg, twice a day, given during 12 months on the fibrosis related to HCV chronic hepatitis in 100 patients who are non-long-term responders, or with contra-indication or intolerance to the current treatment of reference combination with interferon-alfa and ribavirin. It is a therapeutic, national, multicentric, double-blind, placebo-controlled phase III trial. The patients included had histological liver injuries with a Metavir score of A 0 to 2, F 2 or 3 and no other etiology of liver disease. The primary objective is to analyse the variation of the liver fibrosis evaluated by morphometric analysis between the 2 liver biopsies performed at the end of the trial and within 3 years before the treatment. The secondary objectives are the variation of the Metavir fibrosis and activity scores, of serum markers of fibrosis hyaluronate, PIIIP, TNF-alfa, fibrotest and ALT between the end and the beginning of the treatment. 